Olivier Theisen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9373259/publications.pdf

Version: 2024-02-01

		1684188	1474206
16	86	5	9
papers	citations	h-index	g-index
17	17	17	219
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Emergence and evolution of <i>TP53</i> mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica, 2018, 103, e143-e146.	3.5	41
2	Flow cytometry in the diagnosis of mature Bâ€eell lymphoproliferative disorders. International Journal of Laboratory Hematology, 2020, 42, 113-120.	1.3	11
3	Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. Haematologica, 2021, 106, 701-707.	3.5	10
4	<scp>CD200 /scp> expression in flow cytometry helps to distinguish mantle cell lymphoma from other <scp>CD /scp>5â€positive <scp>B</scp>â€ell neoplasms. Hematological Oncology, 2018, 36, 607-609.</scp></scp>	1.7	7
5	No survival improvement in patients with highâ€risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. British Journal of Haematology, 2021, 194, 635-638.	2.5	7
6	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the <scp>LYSA</scp> group. Hematological Oncology, 2020, 38, 446-455.	1.7	5
7	Interest of the XN-10® Analyzer to Screen for Myelodysplastic Syndromes on Complete Blood Count (CBC) Especially with Hemoglobin Levels and Neut-WX. Blood, 2016, 128, 5518-5518.	1.4	3
8	A blueberry muffin rash at birth. British Journal of Haematology, 2018, 182, 168-168.	2.5	1
9	Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma. Annals of Hematology, 2021, 100, 285-287.	1.8	1
10	Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group. Blood, 2018, 132, 4099-4099.	1.4	0
11	Fms-like Tyrosine Kinase 3 Ligand Concentration Kinetic Profile during Induction Is Strongly Predictive of Survivals in AML: Results of the FLAM/Flal Study. Blood, 2018, 132, 1484-1484.	1.4	0
12	A New Cytokine-Based Stratification Is Highly Predictive of Survivals in AML Patients. Blood, 2019, 134, 1412-1412.	1.4	0
13	Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies. Blood, 2019, 134, 5771-5771.	1.4	0
14	Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy. Blood, 2021, 138, 3465-3465.	1.4	0
15	Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study. Blood, 2020, 136, 15-17.	1.4	0
16	Lineage switch and relapse in sanctuary site: Some lessons to learn about plasticity in <i>KMT2Ar</i> acute leukemia. Pediatric Blood and Cancer, 2022, 69, e29683.	1.5	0